ĐẶC ĐIỂM LÂM SÀNG VÀ ĐÁNH GIÁ KẾT QUẢ ĐIỀU TRỊ BỆNH NHÂN ĐỘNG KINH BẰNG LEVETIRACETAM TẠI BỆNH VIỆN ĐA KHOA TỈNH TRÀ VINH

Abstract

Background: epilepsy is a common neurological disease globally and it accounted for 1% of the world’s disease burden. Levetiracetam is an anti-epilepsy drug proven good effectiveness for treating all kind of epilepsy. Objectives: describe the clinical characteristics of epileptic patients at Tra Vinh Province General Hospital in 2021-2022; Evaluation of the results of Levetiracetam in epileptic patients. Materials and method: cross-sectional study including 101 epileptic patients at Tra Vinh Province General Hospital from March 2021 to February 2022. Results: the proportion of idiopathic epilepsy was highest with 66,3%. In addition, 64,4% of patients were first diagnosed with epilepsy and 90,1% experienced their first seizure at the age of higher than 18 years old. Furthermore, patients with aura were 79,2%. Foaming was found in 67,3% of patients in their seizure then 53,3% of cases were exhausted and slept after that. The most common trigger was missing medication with 26,7% cases. After treatment, 88,1% of patients had good outcome. Most of them did not get any side effects and 33,7% of patients had ones which were mild and transient. Conclusion: the prevalent clinical characteristics were the age of onset higher than 18 years old, first seizure, aura, foaming in seizure, exhausted, slept after seizure and idiopathic epilepsy. After received Levetiracetam, the rate of good response was 88,1% and 33,7% of patients had side effects which were mild, transient and disappeared within 4 weeks.